Stock Pulse
Boston Scientific (BSX) is anticipated to announce Q1 2025 earnings on April 23rd, with projected EPS and revenue growth of 19.64% and 18.2% year-over-year, respectively [2], [3]. The company saw a 6.8% stock surge due to optimism surrounding the upcoming earnings [3], though the consensus EPS estimate remains unchanged [3]. While a strong buy recommendation exists from brokerage firms, the Zacks Rank remains at Hold (#3) due to unchanged earnings estimates [4]. BSX demonstrated strong Q4 results with increased sales and income, despite market uncertainties affecting the stock price [7]. The company exhibits strong organic revenue growth, averaging 14.4% over the past two years, with healthy free cash flow [10]. Fidelity increased their passive ownership stake in BSX to approximately 9.6% [11].